Related references
Note: Only part of the references are listed.The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
Emily B. Heikamp et al.
BLOOD (2022)
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
Raghuveer Singh Mali et al.
HAEMATOLOGICA (2021)
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
David A. Sallman et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Courtney D. DiNardo et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
Nico Gagelmann et al.
FRONTIERS IN IMMUNOLOGY (2021)
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome
Mahesh Swaminathan et al.
HAEMATOLOGICA (2021)
Randomized, double-blind, placebo (PL)-controlled, phase III trial of pimitespib (TAS-116), an oral inhibitor of heat shock protein 90 (HSP90), in patients (pts) with advanced gastrointestinal stromal tumor (GIST) refractory to imatinib (IM), sunitinib (SU) and regorafenib (REG).
Yoshitaka Honma et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
Gail J. Roboz et al.
BLOOD (2020)
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia
Szymon Klossowski et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia
Hannah J. Uckelmann et al.
SCIENCE (2020)
Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia
Melat T. Gebru et al.
BLOOD (2020)
Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition
Margarita M. Dzama et al.
BLOOD (2020)
Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma
Ingo K. Mellinghoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression
Alison R. Walker et al.
CLINICAL CANCER RESEARCH (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia
Christine M. McMahon et al.
CANCER DISCOVERY (2019)
Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia
Katherine Tarlock et al.
CLINICAL CANCER RESEARCH (2019)
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E. Cortes et al.
LANCET ONCOLOGY (2019)
The role of TP53 in acute myeloid leukemia: Challenges and opportunities
Karina Barbosa et al.
GENES CHROMOSOMES & CANCER (2019)
A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia
Andrei V. Krivtsov et al.
CANCER CELL (2019)
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia
Maro Ohanian et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
Eytan M. Stein et al.
BLOOD (2018)
Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study
Yasuhiko Harada et al.
LEUKEMIA RESEARCH (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia
Kerstin M. Kampa-Schittenhelm et al.
Oncotarget (2018)
Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3
Kozo Nagai et al.
Oncotarget (2018)
Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia
Kazuhiro Katayama et al.
Oncotarget (2018)
Inactivation of PBX3 and HOXA9 by down-regulating H3K79 methylation represses NPM1-mutated leukemic cell survival
Wu Zhang et al.
THERANOSTICS (2018)
Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions
Eytan M. Stein et al.
BLOOD (2018)
Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM)
Jason R. Gotlib et al.
BLOOD (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia
C. Dafflon et al.
LEUKEMIA (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death
Sook-Kyoung Heo et al.
SCIENTIFIC REPORTS (2017)
Mixed-Lineage Leukemia Fusions and Chromatin in Leukemia
Andrei V. Krivtsov et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Knockdown of HSPA9 induces TP53dependent apoptosis in human hematopoietic progenitor cells
Tuoen Liu et al.
PLOS ONE (2017)
Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients
Mark R. Woodford et al.
EMBO JOURNAL (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia
Sebastian Mohr et al.
CANCER CELL (2017)
Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia
Norio Shiba et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Deregulation of the HOXA9/MEIS1 axis in acute leukemia
Cailin T. Collins et al.
CURRENT OPINION IN HEMATOLOGY (2016)
Discovery of Novel Inhibitors Targeting the Menin-Mixed Lineage Leukemia Interface Using Pharmacophore- and Docking-Based Virtual Screening
Yuan Xu et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2016)
Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells
Maryam Abbaspour Babaei et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
Paolo Strati et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo
Dmitry Borkin et al.
CANCER CELL (2015)
MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition
Michael W. M. Kuehn et al.
HAEMATOLOGICA (2015)
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Steven M. Chan et al.
NATURE MEDICINE (2015)
Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia
Katalin Boros et al.
ONCOTARGET (2015)
MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition
Michael W. M. Kuehn et al.
HAEMATOLOGICA (2015)
TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
Shuichi Ohkubo et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Allison Galanis et al.
BLOOD (2014)
Preclinical efficacy of MEK inhibition in Nras-mutant AML
Michael R. Burgess et al.
BLOOD (2014)
SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
Alexandre Puissant et al.
CANCER CELL (2014)
Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
Nitin Jain et al.
CLINICAL CANCER RESEARCH (2014)
Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia
Marina Y. Konopleva et al.
CLINICAL CANCER RESEARCH (2014)
Ponatinib Induces Apoptosis in Imatinib-Resistant Human Mast Cells by Dephosphorylating Mutant D816V KIT and Silencing β-Catenin Signaling
Bei Jin et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Scott R. Daigle et al.
BLOOD (2013)
β2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis
Thomas Oellerich et al.
BLOOD (2013)
Targeting Recruitment of Disruptor of Telomeric Silencing 1-like (DOT1L) CHARACTERIZING THE INTERACTIONS BETWEEN DOT1L AND MIXED LINEAGE LEUKEMIA (MLL) FUSION PROTEINS
Chenxi Shen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
FLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice
Emily Bailey et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Treatment of infant leukemias: challenge and promise
Patrick Brown
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients
M. M. Patnaik et al.
LEUKEMIA (2012)
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu et al.
NATURE (2012)
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia
Jolanta Grembecka et al.
NATURE CHEMICAL BIOLOGY (2012)
Regulation of RAS oncogenicity by acetylation
Moon Hee Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Puma, a critical mediator of cell death - one decade on from its discovery
Pawe Hikisz et al.
CELLULAR & MOLECULAR BIOLOGY LETTERS (2012)
NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights
Sheryl M. Gough et al.
BLOOD (2011)
Germline KRAS Mutations Cause Aberrant Biochemical and Physical Properties Leading to Developmental Disorders
Lothar Gremer et al.
HUMAN MUTATION (2011)
Mechanisms of STAT Protein Activation by Oncogenic KIT Mutants in Neoplastic Mast Cells
Amandine Chaix et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
NPM1/B23: AMultifunctional Chaperone in Ribosome Biogenesis and Chromatin Remodeling
Mikael S. Lindstrom
BIOCHEMISTRY RESEARCH INTERNATIONAL (2011)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
A Robust Error Model for iTRAQ Quantification Reveals Divergent Signaling between Oncogenic FLT3 Mutants in Acute Myeloid Leukemia
Yi Zhang et al.
MOLECULAR & CELLULAR PROTEOMICS (2010)
PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
Jeremy M. R. Lambert et al.
CANCER CELL (2009)
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
Ravindra Majeti et al.
CELL (2009)
Acute myeloid leukemia bearing t(7;11)(p15;p15) is a distinct cytogenetic entity with poor outcome and a distinct mutation profile: comparative analysis of 493 adult patients
W-C Chou et al.
LEUKEMIA (2009)
Clinical implications of c-Kit mutations in acute myelogenous leukemia
Muriel Malaise et al.
Current Hematologic Malignancy Reports (2009)
Menin critically links MLL proteins with LEDGE on cancer-associated target genes
Akihiko Yokoyama et al.
CANCER CELL (2008)
Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia
Matthew G. Guenther et al.
GENES & DEVELOPMENT (2008)
HOX expression patterns identify a common signature for favorable AML
M. Andreeff et al.
LEUKEMIA (2008)
Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias
C. G. Mullighan et al.
LEUKEMIA (2007)
NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis
Gang G. Wang et al.
NATURE CELL BIOLOGY (2007)
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Marina Konopleva et al.
CANCER CELL (2006)
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML
Brunangelo Falini et al.
BLOOD (2006)
Prognostic impact of c-KIT mutations in core binding factor leukemas:: an Italian retrospective study
R Cairoli et al.
BLOOD (2006)
The SIRP family of receptors and immune regulation
AN Barclay et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications
TA Milne et al.
CANCER RESEARCH (2005)
The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis
A Yokoyama et al.
CELL (2005)
FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model
R Grundler et al.
BLOOD (2005)
hDOT1L links histone methylation to leukemogenesis
Y Okada et al.
CELL (2005)
When epigenetics kills: MLL fusion proteins in leukemia
RK Slany
HEMATOLOGICAL ONCOLOGY (2005)
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
B Falini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Definitive hematopoiesis requires the mixed-lineage leukemia gene
P Ernst et al.
DEVELOPMENTAL CELL (2004)
An MII-dependent Hox program drives hematopoietic progenitor expansion
P Ernst et al.
CURRENT BIOLOGY (2004)
Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1
N Pineault et al.
BLOOD (2003)
Bcl-2-family proteins and the role of mitochondria in apoptosis
T Kuwana et al.
CURRENT OPINION IN CELL BIOLOGY (2003)
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics
A Letai et al.
CANCER CELL (2002)
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
SA Armstrong et al.
NATURE GENETICS (2002)
Share Paper
